Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine during electroconvulsive therapy in schizophrenia
IRCT20250109064331N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in schizophrenia comparing Caffeine with Placebo (2 arms). Primary endpoints: Seizure duration during ECT and Severity of psychotic symptoms. Started Jan 2025; status: completed.
02
Drugs
caffeine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20250109064331N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250109064331N1.